The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06, Zacks reports. 181,566 shares of the company’s stock were exchanged, compared to its average volume of 557,097. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the period. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.